JP2013542258A - アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態 - Google Patents

アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態 Download PDF

Info

Publication number
JP2013542258A
JP2013542258A JP2013538839A JP2013538839A JP2013542258A JP 2013542258 A JP2013542258 A JP 2013542258A JP 2013538839 A JP2013538839 A JP 2013538839A JP 2013538839 A JP2013538839 A JP 2013538839A JP 2013542258 A JP2013542258 A JP 2013542258A
Authority
JP
Japan
Prior art keywords
crystalline
acid
ethyl
methyl
mercapto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013538839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542258A5 (https=
Inventor
ポール アール． ファザリー，
ヴァンキャット アール． サラディー，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2013542258A publication Critical patent/JP2013542258A/ja
Publication of JP2013542258A5 publication Critical patent/JP2013542258A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013538839A 2010-11-10 2011-11-09 アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態 Pending JP2013542258A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
US61/412,011 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015174397A Division JP2016028061A (ja) 2010-11-10 2015-09-04 アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態

Publications (2)

Publication Number Publication Date
JP2013542258A true JP2013542258A (ja) 2013-11-21
JP2013542258A5 JP2013542258A5 (https=) 2014-11-06

Family

ID=45003086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538839A Pending JP2013542258A (ja) 2010-11-10 2011-11-09 アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態
JP2015174397A Pending JP2016028061A (ja) 2010-11-10 2015-09-04 アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015174397A Pending JP2016028061A (ja) 2010-11-10 2015-09-04 アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態

Country Status (19)

Country Link
US (3) US8362060B2 (https=)
EP (1) EP2638017B1 (https=)
JP (2) JP2013542258A (https=)
KR (1) KR20130130730A (https=)
CN (1) CN103189362B (https=)
AR (1) AR083828A1 (https=)
AU (1) AU2011326622B2 (https=)
BR (1) BR112013011715A2 (https=)
CA (1) CA2812598A1 (https=)
CO (1) CO6741224A2 (https=)
ES (1) ES2567721T3 (https=)
IL (1) IL225303A0 (https=)
MX (1) MX2013005165A (https=)
NZ (1) NZ609804A (https=)
PH (1) PH12013500945A1 (https=)
RU (1) RU2013126403A (https=)
SG (1) SG189448A1 (https=)
TW (1) TW201300366A (https=)
WO (1) WO2012064807A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518429A (ja) * 2021-05-11 2024-05-01 アステックス ファーマシューティカルズ インコーポレイテッド ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010039719A1 (en) * 2008-09-30 2010-04-08 Theravance, Inc. Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
JP2010526774A (ja) * 2007-04-24 2010-08-05 セラヴァンス， インコーポレーテッド 二重の作用を有する血圧降下剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526774A (ja) * 2007-04-24 2010-08-05 セラヴァンス， インコーポレーテッド 二重の作用を有する血圧降下剤
WO2010039719A1 (en) * 2008-09-30 2010-04-08 Theravance, Inc. Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0003103521 *
ADVANCED DRUG DELIVERY REVIEWS, vol. ５６, JPN6015025722, 2004, pages 275 - 300, ISSN: 0003103525 *
BERGE，S. M.: "Pharmaceutical salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN5004004439, 1977, US, pages 1 - 19, ISSN: 0003103526 *
大島寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0003103522 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0003103524 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0003103520 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0003103523 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518429A (ja) * 2021-05-11 2024-05-01 アステックス ファーマシューティカルズ インコーポレイテッド ４－［５－［（３ｓ）－３－アミノピロリジン－１－カルボニル］－２－［２－フルオロ－４－（２－ヒドロキシ－２－エチルプロピル）フェニル］フェニル］－２－フルオロ－ベンゾニトリルの塩の固体形態

Also Published As

Publication number Publication date
AR083828A1 (es) 2013-03-27
BR112013011715A2 (pt) 2017-10-31
CO6741224A2 (es) 2013-08-30
PH12013500945A1 (en) 2013-07-08
TW201300366A (zh) 2013-01-01
AU2011326622B2 (en) 2014-12-18
HK1187919A1 (zh) 2014-04-17
EP2638017B1 (en) 2016-01-27
RU2013126403A (ru) 2014-12-20
US20120115920A1 (en) 2012-05-10
JP2016028061A (ja) 2016-02-25
MX2013005165A (es) 2013-07-05
US9249105B2 (en) 2016-02-02
US8362060B2 (en) 2013-01-29
US20130267573A1 (en) 2013-10-10
KR20130130730A (ko) 2013-12-02
ES2567721T3 (es) 2016-04-26
CN103189362A (zh) 2013-07-03
NZ609804A (en) 2015-02-27
CA2812598A1 (en) 2012-05-18
AU2011326622A1 (en) 2013-04-04
US20150133518A1 (en) 2015-05-14
IL225303A0 (en) 2013-06-27
WO2012064807A1 (en) 2012-05-18
US8802709B2 (en) 2014-08-12
CN103189362B (zh) 2015-03-11
EP2638017A1 (en) 2013-09-18
SG189448A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
JP2011529072A (ja) 二重作用血圧降下薬
JP2018203761A (ja) ネプリライシン阻害剤
JP2011518884A (ja) 二重活性抗高血圧剤
JP2010538071A (ja) 二重作用性降圧剤
JP2012533626A (ja) 二重作用オキサゾール降圧剤
US11033533B2 (en) (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
JP2020180147A (ja) ネプリライシン阻害剤としての（２ｓ，４ｒ）−５−（５’−クロロ−２’−フルオロビフェニル−４−イル）−４−（エトキシオキサリルアミノ）−２−ヒドロキシメチル−２−メチルペンタン酸
JP5495396B2 (ja) アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶形
JP2016028061A (ja) アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶性形態
US10472335B2 (en) Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-bipheny]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
HK1187919B (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160215